The company has less than 2 months of cash runway at current burn rates without additional financing. Watch for near-term equity dilution through the ATM program (up to $3.8 million) or a strategic transaction. The December 2026 NDS filing in Canada is a binary catalyst but requires funding to execute.
Price Chart
Executive Summary
NeuroSense Therapeutics reported H1 2026 financial results showing a net loss of $3.6 million (improved from $4.7 million in H1 2025), with cash of only $0.2 million as of June 30, 2026. The filing reiterates a going concern warning and substantial doubt about the company's ability to continue, while highlighting positive clinical data for PrimeC in ALS and a planned NDS filing in Canada targeting December 2026. The company has no revenue and requires additional financing to fund operations beyond the near term.
Key Facts
- Cash and cash equivalents of $231 thousand as of June 30, 2026, down from $166 thousand at December 31, 2025
- Net loss of $3.6 million for H1 2026, improved from $4.7 million in H1 2025
- Accumulated deficit of $51.3 million as of June 30, 2026
- Negative working capital of $2.2 million as of June 30, 2026
- Substantial doubt raised about ability to continue as a going concern
- Cash resources not sufficient to fund operations for 12 months from approval of financial statements
- Received Nasdaq non-compliance notice on April 2, 2026 for minimum bid price and MVLS requirements
- Effected 1-for-20 reverse share split on September 14, 2026
- Targeting December 2026 NDS filing for PrimeC in Canada
- Phase 3 PARAGON trial enrollment anticipated in Q3 2027, subject to funding
- Cost-reduction measures implemented in June 2026 including workforce reduction
- No revenue generated to date
Financial Impact
Cash burn rate of approximately $1.99 million in operating cash flow over H1 2026; only $0.2 million cash remaining; going concern risk is acute
Risk Factors
- Going concern risk — cash insufficient to fund operations for 12 months
- Nasdaq delisting risk if compliance not regained by September 29, 2026
- Dilution risk from ATM program and potential future equity offerings
- Clinical and regulatory risk — PrimeC may not receive regulatory approval
- Financing risk — no assurance of obtaining additional capital on acceptable terms
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-103534 |
| Document: ea030656401ex99-3.htm | 0001213900-26-103534 |
| Document: ea030656401ex99-1.htm | 0001213900-26-103534 |
| Document: ea0306564-6k_neurosense.htm | 0001213900-26-103534 |
| Document: 0001213900-26-103534-index-headers.html | 0001213900-26-103534 |
| Document: 0001213900-26-103534-index.html | 0001213900-26-103534 |
| Document: 0001213900-26-103534.txt | 0001213900-26-103534 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $2.67 $2.39 | ▼ −10.32% | ▼ −10.65% | $2.46 (−7.69%) |
Oct 13, 2026 13d ago | 6-K | $3.49 $3.06 | ▼ −12.32% | ▼ −11.24% | $2.46 (−29.51%) |
Sep 25, 2026 4w ago | 6-K | $5.10 $4.78 | ▲ +6.27% | ▲ +6.09% | $2.46 (+51.76%) |
Aug 6, 2026 11w ago | 6-K | $0.5030 $0.4999 | ▼ −0.62% | ▼ −1.23% | $2.46 (+389.07%) |
Jul 22, 2026 13w ago | 6-K | $0.6500 $0.6550 | ▲ +0.77% | ▲ +2.00% | $2.46 (+278.46%) |
Jun 29, 2026 17w ago | 6-K | $0.7099 $0.7200 | ▲ +1.42% | ▲ +0.64% | $2.46 (+246.53%) |
Jun 17, 2026 18w ago | Insider Cluster | $16.10 $15.78 | ▼ −1.99% | ▼ −1.67% | $2.46 (−84.72%) |
Jun 11, 2026 19w ago | 6-K | $0.7390 $0.7352 | ▼ −0.51% | ▼ −1.05% | $2.46 (+232.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers